数据挖掘BLQ复方中药联合化疗治疗原发性肝癌的临床观察  

Clinical observation of data mining BLQ combined chemotherapy in the treatment of primary carcinoma of the liver

作　　者：付烊 赵旭 刘亚琪 胡梦云[1] 朱学明 乔占兵 FU Yang;ZHAO Xu;LIU Ya-qi;HU Meng-yun;ZHU Xue-ming;QIAO Zhan-bing(Oncology Department,Xiangyang Chinese Medicine Hospital,Xiangyang 441000,China;PHD Student of Class 2018 Hubei University of Chinese Medicine,Wuhan 430065,China;Oncology Department,Dongfang Hospital,Beijing University of Traditional Chinese Medicine,Beijing 100078,China)

机构地区：[1]湖北省襄阳市中医医院肿瘤科,襄阳441000 [2]湖北中医药大学,2018级博士研究生武汉430065 [3]北京中医药大学附属东方医院肿瘤科,北京100078

出　　处：《中华中医药杂志》2018年第11期5249-5252,共4页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：湖北省卫计委2016-2017年度中医药中西医结合科研重点项目~~

摘　　要：目的:观察数据挖掘BLQ复方中药联合化疗治疗中晚期原发性肝癌的临床效果。方法:以2014年12月至2017年12月在襄阳市中医院治疗的中晚期原发性肝癌患者为观察对象,根据其治疗方案分为BLQ方案组、BLQ方案+化疗组和单纯化疗组,每组各25例。比较3组患者生存率、治疗前后肿瘤标志物和生活质量的差异。结果:BLQ复方中药+化疗组患者3个月、6个月和12个月生存率明显高于BLQ方案组和单纯化疗组(P<0.05);3组患者治疗后AFP、CA199和CEA均有所下降,且BLQ方案+化疗组患者下降更为明显(P<0.05);3组患者治疗后生活质量各维度得分均增加,且BLQ方案+化疗组患者升高更为明显(P<0.05);BLQ方案+化疗组和BLQ方案组患者不良反应的发生例数明显低于单纯化疗组(P<0.05)。结论:BLQ方案+化疗药物诱导联合治疗对中晚期原发性肝癌能延长生存期,降低肿瘤标志物水平,提高患者的生活质量。协同治疗可能会提高肝癌化疗有效率。Objective： To observe the effect of data mining BLQ combined chemotherapy in the treatment of middle and late primary carcinoma of the liver. Methods： Liver cancer patients treated in Xiangyang Chinese Medicine Hospital from December 2014 to December 2017 were selected as the observation object, according to the treatment plan which is divided into BLQ solution group, BLQ＋chemotherapy group and chemotherapy group, 25 cases in each group. The differences of tumor markers and quality of life were compared between the three groups before and after treatment. Results： BLQ＋chemotherapy group patients survival rate was significantly higher than the BLQ group and chemotherapy group in 3 months, 6 months and 12 months. The AFP CA199 and CEA were declined after treatment and BLQ＋chemotherapy group were decreased more significantly（P0.05）. After treatment, the quality of life of patients in three groups dimension scores were increased and BLQ＋ chemotherapy group increased more obvious（P0.05）. The incidence of adverse reactions was significantly lower in the patients with BLQ ＋chemotherapy group and BLQ program group than in the chemotherapy group（P0.05）. Conclusion： The combination of BLQ program and chemotherapy can significantly reduce the level of tumor markers and improve the quality of life of middle or late liver cancer patients. Combined chemotherapy therapy may improve the efficiency of liver cancer therapy.

关 键 词：数据挖掘 BLQ方案 肝癌 化疗 补气健脾 理气化疗 清热解毒 

分 类 号：R735.7[医药卫生—肿瘤]